Sydney, Dec 12, 2007 -- Peplin Inc (ASX:PLI) has positive preliminary results for PEP005-007 for its phase IIa actinic keratosis clinical trial. The trial, for Peplin's patient-applied topical gel, has been tested on the face and scalp as therapy for pre-cancerous skin lesions caused by sun exposure.
